<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="cam470978" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Med</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2045-7634</journal-id><journal-id journal-id-type="publisher-id">CAM4</journal-id><journal-title-group><journal-title>Cancer Medicine</journal-title></journal-title-group><issn pub-type="epub">2045-7634</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40396416</article-id><article-id pub-id-type="pmc">PMC12093152</article-id><article-id pub-id-type="doi">10.1002/cam4.70978</article-id><article-id pub-id-type="publisher-id">CAM470978</article-id><article-id pub-id-type="other">CAM4-2024-05-2565.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Tertiary Lymphoid Structures as Independent Predictors of Favorable Prognosis in Muscle&#x02010;Invasive Bladder Cancer</article-title></title-group><contrib-group><contrib id="cam470978-cr-0001" contrib-type="author" corresp="yes"><name><surname>Teng</surname><given-names>Xiaodong</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8700-4770</contrib-id><xref rid="cam470978-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>teng1102069@zju.edu.cn</email></address></contrib><contrib id="cam470978-cr-0002" contrib-type="author"><name><surname>Chen</surname><given-names>Zhen</given-names></name><xref rid="cam470978-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470978-cr-0003" contrib-type="author"><name><surname>Bai</surname><given-names>Yanfeng</given-names></name><xref rid="cam470978-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470978-cr-0004" contrib-type="author"><name><surname>Cao</surname><given-names>Hui</given-names></name><xref rid="cam470978-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470978-cr-0005" contrib-type="author"><name><surname>Zhang</surname><given-names>Jing</given-names></name><xref rid="cam470978-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470978-cr-0006" contrib-type="author"><name><surname>Xu</surname><given-names>Liming</given-names></name><xref rid="cam470978-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470978-cr-0007" contrib-type="author"><name><surname>Liu</surname><given-names>Kaihua</given-names></name><xref rid="cam470978-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cam470978-cr-0008" contrib-type="author"><name><surname>Shi</surname><given-names>Yuqian</given-names></name><xref rid="cam470978-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cam470978-cr-0009" contrib-type="author"><name><surname>Shao</surname><given-names>Yang</given-names></name><xref rid="cam470978-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="cam470978-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology, the First Affiliated Hospital</named-content>
<institution>Zhejiang University School of Medicine</institution>
<city>Hangzhou</city>
<country country="CN">China</country>
</aff><aff id="cam470978-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Nanjing Geneseeq Technology Inc.</institution>
<city>Nanjing</city>
<named-content content-type="country-part">Jiangsu</named-content>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Xiaodong Teng (<email>teng1102069@zju.edu.cn</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><volume>14</volume><issue seq="490">10</issue><issue-id pub-id-type="doi">10.1002/cam4.v14.10</issue-id><elocation-id>e70978</elocation-id><history>
<date date-type="rev-recd"><day>02</day><month>9</month><year>2024</year></date>
<date date-type="received"><day>05</day><month>5</month><year>2024</year></date>
<date date-type="accepted"><day>11</day><month>5</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 Published by John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Cancer Medicine</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:CAM4-14-e70978.pdf"/><abstract><title>ABSTRACT</title><sec id="cam470978-sec-0001"><title>Background</title><p>Tertiary lymphoid structure (TLS) has been reported to be associated with prognosis and immunotherapy in certain cancers. The objective of our study was to investigate the prognostic significance of Tertiary Lymphoid Structures (TLS) within the context of Muscle&#x02010;Invasive Bladder Cancer (MIBC), while concurrently examining the clinicopathological and molecular determinants influencing TLS formation.</p></sec><sec id="cam470978-sec-0002"><title>Methods</title><p>Immunohistochemistry was used to detect the expression of TLS, CD8+ T cells, B cells, and plasma cells in 119 MIBC cases, of which 80 cases were tested by next generation sequencing (NGS) for analyzing the differences in gene alterations between TLS&#x02010;negative and TLS&#x02010;positive.</p></sec><sec id="cam470978-sec-0003"><title>Results</title><p>TLS were identified in 52.1% (62/119) of the MIBC cases studied. Patients exhibiting TLS demonstrated reduced T and TNM staging and prolonged overall survival (OS) compared to those lacking TLS. Multivariate analysis showed that TLS was an independent prognostic factor. Densities of B cells, CD8+ T cells, and plasma cells in tumors were significantly correlated with TLS, but in the cases with low&#x02010;density B cells, high&#x02010;density CD8+ T cells, or high&#x02010;density plasma cells, differences in OS between the tumors with TLS and without TLS were not significant. Compared with TLS&#x02010;negative tumors, TLS&#x02010;positive tumors had a lower frequency of <italic toggle="no">TP53</italic> mutations and higher frequencies of <italic toggle="no">FAT1</italic> and <italic toggle="no">CDKN1A</italic> mutations. Tumor mutational burden (TMB) was not significantly different between the two groups but was significantly associated with TLS in <italic toggle="no">TP53</italic> wild&#x02010;type tumors.</p></sec><sec id="cam470978-sec-0004"><title>Conclusions</title><p>TLS emerged as an independent harbinger of favorable prognosis in MIBC, predominantly mediating antitumor responses via B cells. Moreover, <italic toggle="no">TP53</italic> mutations were identified as a potential inhibitor of TLS formation.</p></sec></abstract><abstract abstract-type="graphical"><p>Tertiary lymphoid structure (TLS) was an independent predictor of favorable prognosis in MIBC, and mainly played antitumor role effect through B cells. Through NGS analysis of tumor samples, we also believe that TP53 mutations could inhibit the formation of TLS.<boxed-text position="anchor" content-type="graphic" id="cam470978-blkfxd-0001"><graphic xlink:href="CAM4-14-e70978-g002.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cam470978-kwd-0001">tertiary lymphoid structures</kwd><kwd id="cam470978-kwd-0002">TP53 genes</kwd><kwd id="cam470978-kwd-0003">tumor microenvironment</kwd><kwd id="cam470978-kwd-0004">urinary bladder neoplasms</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Zhejiang Provincial Natural Science Foundation of China
</institution><institution-id institution-id-type="doi">10.13039/501100017623</institution-id></institution-wrap></funding-source><award-id>LQ19H160038</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Zhejiang Provincial Research Center for Cancer Intelligent Diagnosis and Molecular Technology
</institution><institution-id institution-id-type="doi">10.13039/100020734</institution-id></institution-wrap></funding-source><award-id>JBZX&#x02010;202003</award-id></award-group></funding-group><counts><fig-count count="5"/><table-count count="2"/><page-count count="8"/><word-count count="4200"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:21.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="cam470978-ntgp-0001"><fn fn-type="funding" id="cam470978-note-0001"><p>
<bold>Funding:</bold> This study was supported by Zhejiang Provincial Research Center for Cancer Intelligent Diagnosis and Molecular Technology (JBZX&#x02010;202003) and Zhejiang Provincial Natural Science Foundation of China (No. LQ19H160038).</p></fn></fn-group></notes></front><body id="cam470978-body-0001"><sec sec-type="background" id="cam470978-sec-0005"><label>1</label><title>Background</title><p>Bladder cancer, with its invasive muscle phenotype, stands as a formidable challenge in oncology due to its aggressive nature and the limited efficacy of current treatment options. Muscle&#x02010;invasive bladder cancer (MIBC) marks a critical stage where the tumor's metastatic potential sharply escalates, demanding the identification of novel prognostic markers and therapeutic targets [<xref rid="cam470978-bib-0001" ref-type="bibr">1</xref>].</p><p>Within the complex landscape of the tumor microenvironment (TME), the presence of tertiary lymphoid structures (TLS) has garnered significant attention. These immune cell clusters resemble lymphoid tissues and are found within the supportive stroma of diverse solid tumors. They are believed to regulate local immune responses, potentially shaping the course of cancer progression and the effectiveness of immunotherapeutic approaches [<xref rid="cam470978-bib-0002" ref-type="bibr">2</xref>, <xref rid="cam470978-bib-0003" ref-type="bibr">3</xref>, <xref rid="cam470978-bib-0004" ref-type="bibr">4</xref>, <xref rid="cam470978-bib-0005" ref-type="bibr">5</xref>].</p><p>Emerging evidence suggests that the presence of TLS is associated with improved prognosis and is more frequently observed in MIBC than in non&#x02010;muscle&#x02010;invasive forms of the disease [<xref rid="cam470978-bib-0005" ref-type="bibr">5</xref>, <xref rid="cam470978-bib-0006" ref-type="bibr">6</xref>, <xref rid="cam470978-bib-0007" ref-type="bibr">7</xref>]. This has led to the hypothesis that TLS may have a correlation with tumor aggressiveness. Such findings have ignited further inquiry into the mechanisms influencing the clinical trajectory of MIBC and the potential of TLS as prognostic biomarkers.</p><p>By undertaking a thorough examination of TLS in MIBC, we further advance this field. To this end, we aim to delineate the correlation between TLS and clinical outcomes, thus providing a more nuanced understanding of their prognostic importance and their interplay with the clinicopathological and molecular aspects of MIBC. This investigation is poised to enhance our understanding of the role of TLS in MIBC.</p></sec><sec sec-type="methods" id="cam470978-sec-0006"><label>2</label><title>Methods</title><sec id="cam470978-sec-0007"><label>2.1</label><title>Patients</title><p>The study cohort comprised 119 patients diagnosed with MIBC and treated with radical cystectomy at the First Affiliated Hospital of Zhejiang University School of Medicine from 2016 to 2018. All cases were re&#x02010;evaluated by two experienced pathologists (Y.B and X.T) to confirm treatment na&#x000ef;vet&#x000e9; at the time of study entry. Twenty representative 4&#x02009;&#x003bc;m&#x02010;thick sections from formalin&#x02010;fixed paraffin&#x02010;embedded (FFPE) tumor blocks were selected for subsequent immunohistochemical and next&#x02010;generation sequencing (NGS) analyses. Tumor staging adhered to the Eighth Edition of the Union for International Cancer Control/American Joint Committee on Cancer guidelines, with patient survival data collected through December 2019. The peripheral blood neutrophil and lymphocyte counts, obtained from clinical records within 2&#x02009;weeks post&#x02010;surgery, were used to calculate the Neutrophil&#x02010;to&#x02010;Lymphocyte Ratio (NLR), with the high and low NLR groups defined by the median value of 2.82 from all measurements. The study protocol was approved by the hospital's Ethics Committee and aligned with the Declaration of Helsinki principles.</p></sec><sec id="cam470978-sec-0008"><label>2.2</label><title>
<styled-content style="fixed-case" toggle="no">TLS</styled-content> Evaluation</title><p>The presence and maturity of TLS were evaluated in a blinded manner by two pathologists using CD3&#x02010;CD20 immunohistochemical staining, with discrepancies resolved by consensus. TLS was defined as aggregates exceeding 50 B and T lymphocytes, with mature TLS (mTLS) distinguished by the presence of germinal centers on hematoxylin and eosin&#x02010;stained sections, as previously described [<xref rid="cam470978-bib-0008" ref-type="bibr">8</xref>]. TLS density was calculated as the number of TLS per tumor area using a slice scanning system (Konfoong Biotech, Ningbo, China). Samples were categorized into TLS&#x02010;high or TLS&#x02010;low based on their density relative to the median value of the TLS&#x02010;positive group.</p></sec><sec id="cam470978-sec-0009"><label>2.3</label><title>Immunohistochemistry Staining</title><p>The double CD3&#x02010;CD20 immunohistochemistry staining was performed with the primary antibodies CD3 and CD20 (all antibody information can be found in Table&#x000a0;<xref rid="cam470978-supitem-0002" ref-type="supplementary-material">S1</xref>). The staining procedure was performed with a Bond&#x02010;III Automated IHC Staining System (Leica, Germany) following the manufacturer's recommendations.</p><p>CD8 and CD138 staining were performed with the Bond&#x02010;III Automated IHC Staining System with Bond Polymer Refine detection kits (Leica, Germany), also according to the manufacturer's instructions. Slides were scanned with the PANNORAMIC 250 Flash III DX system (3DHISTECH, Hungary). CD8+ T cell densities were evaluated by pathologists (Y.B) using the QuanCenter automated analysis system (3DHISTECH, Hungary). Plasma cell counts were determined in five high&#x02010;power fields on CD138&#x02010;stained sections, while B cell counts were assessed in 10 high&#x02010;power fields on CD3&#x02010;CD20&#x02010;stained sections, with only CD20&#x02010;stained lymphocytes being scored. Density categorization was based on median cell count. Plasma cell counts were enumerated in five immune cell&#x02010;positive hot 20&#x02009;&#x000d7; fields on CD138&#x02010;stained sections. B cell counts were enumerated in 10 immune cell&#x02010;positive hot 20&#x02009;&#x000d7; fields on CD3&#x02010;CD20&#x02010;stained sections (only the lymphocytes stained with CD20 were scored). Densities were stratified using median cell count as the cutoff.</p><p>PD&#x02010;L1 staining was conducted according to the manufacturer's guidelines for the Ventana Medical Systems (Tucson, AZ, USA). Expression levels were evaluated using the tumor proportion score (TPS), immune cell proportion score (IPS), and combined positive score (CPS) as described by Shitara et&#x000a0;al. [<xref rid="cam470978-bib-0009" ref-type="bibr">9</xref>]. Positive PD&#x02010;L1 scores were defined as 25% or higher.</p></sec><sec id="cam470978-sec-0010"><label>2.4</label><title>Next&#x02010;Generation Sequencing (<styled-content style="fixed-case" toggle="no">NGS</styled-content>)</title><p>NGS was performed on 80 samples, with genomic DNA extracted using the QIAamp DNA FFPE Tissue Kit (Qiagen, Germany). DNA quality was assessed via 1% agarose gel electrophoresis, and degraded samples were excluded. Quantification was achieved using a Qubit 3.0 fluorometer and the Qubit dsDNA HS assay kit (Life Technologies, USA). Library preparation for hybrid&#x02010;based targeted NGS utilized the GeneseeqPrime Kit (Geneseeq, Nanjing, China), covering 425 cancer&#x02010;associated genes listed in Table&#x000a0;<xref rid="cam470978-supitem-0003" ref-type="supplementary-material">S2</xref>. Sequencing was conducted on the Illumina Nextseq550 platform, with data processed using the manufacturer's bioinformatics software. Tumor mutational burden (TMB) and microsatellite instability (MSI) were also assessed.</p></sec><sec id="cam470978-sec-0011"><label>2.5</label><title>Statistical Analysis</title><p>Overall survival (OS) was measured from the date of diagnosis to the date of death or last follow&#x02010;up. Survival analysis was conducted using the Kaplan&#x02013;Meier method with log&#x02010;rank testing and Cox regression. Associations between groups and clinicopathological characteristics were evaluated using chi&#x02010;square or Fisher's exact tests, and nonparametric correlations assessed using the Mann&#x02013;Whitney test. All statistical tests were two&#x02010;sided, with <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 considered significant. Analyses were performed using IBM SPSS 28.0 software (Chicago, USA). R packages &#x02018;maftools&#x02019; and &#x02018;complexheatmap&#x02019; were employed to analyze gene mutation differences between TLS&#x02010;positive and TLS&#x02010;negative cases.</p></sec></sec><sec sec-type="results" id="cam470978-sec-0012"><label>3</label><title>Results</title><sec id="cam470978-sec-0013"><label>3.1</label><title>
<styled-content style="fixed-case" toggle="no">TLS</styled-content> Was a Predictor of Good Prognosis in <styled-content style="fixed-case" toggle="no">MIBC</styled-content>
</title><p>TLSs were identified in 52.1% (62/119) of MIBC cases, predominantly at the tumor periphery, with mature TLS (mTLS) observed in only six cases. The prevalence of TLS showed no association with gender, age, N&#x02010;stage, vascular invasion, nerve invasion, or PD&#x02010;L1 expression. However, a higher incidence of TLS prevalence was observed in cases with lower T&#x02010;stage and TNM stage (Table&#x000a0;<xref rid="cam470978-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="cam470978-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Associations between TLS and investigative factors.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Factor</th><th align="center" valign="bottom" rowspan="1" colspan="1">TLS&#x02010;negative</th><th align="center" valign="bottom" rowspan="1" colspan="1">TLS&#x02010;positive</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="4" valign="top" rowspan="1">Gender</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">52</td><td align="center" valign="top" rowspan="1" colspan="1">51</td><td align="center" valign="top" rowspan="1" colspan="1">0.152</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">Age</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;70&#x02009;year</td><td align="center" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x02265;&#x02009;70&#x02009;year</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">28</td><td align="center" valign="top" rowspan="1" colspan="1">0.114</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">Tumor size</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;3.8&#x02009;cm</td><td align="center" valign="top" rowspan="1" colspan="1">27</td><td align="center" valign="top" rowspan="1" colspan="1">35</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x02265;&#x02009;3.8&#x02009;cm</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">27</td><td align="center" valign="top" rowspan="1" colspan="1">0.322</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">PD&#x02010;L1 (TPS)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Negative</td><td align="center" valign="top" rowspan="1" colspan="1">44</td><td align="center" valign="top" rowspan="1" colspan="1">45</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">0.563</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">PD&#x02010;L1 (IPS)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Negative</td><td align="center" valign="top" rowspan="1" colspan="1">51</td><td align="center" valign="top" rowspan="1" colspan="1">48</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">14</td><td align="center" valign="top" rowspan="1" colspan="1">0.079</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">PD&#x02010;L1 (CPS)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Negative</td><td align="center" valign="top" rowspan="1" colspan="1">40</td><td align="center" valign="top" rowspan="1" colspan="1">39</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">0.402</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">TNM&#x02010;stage</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">II</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">III</td><td align="center" valign="top" rowspan="1" colspan="1">48</td><td align="center" valign="top" rowspan="1" colspan="1">39</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IV</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">0.018</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">T&#x02010;stage</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">24</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">14</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">N&#x02010;stage</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">43</td><td align="center" valign="top" rowspan="1" colspan="1">48</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">0.968</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">Vascular invasion</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Without</td><td align="center" valign="top" rowspan="1" colspan="1">33</td><td align="center" valign="top" rowspan="1" colspan="1">41</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">With</td><td align="center" valign="top" rowspan="1" colspan="1">24</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">0.355</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">Nerve invasion</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Without</td><td align="center" valign="top" rowspan="1" colspan="1">42</td><td align="center" valign="top" rowspan="1" colspan="1">52</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">With</td><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">0.173</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">NLR</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Low</td><td align="center" valign="top" rowspan="1" colspan="1">26</td><td align="center" valign="top" rowspan="1" colspan="1">33</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">High</td><td align="center" valign="top" rowspan="1" colspan="1">31</td><td align="center" valign="top" rowspan="1" colspan="1">29</td><td align="center" valign="top" rowspan="1" colspan="1">0.407</td></tr></tbody></table><table-wrap-foot id="cam470978-ntgp-0002"><fn id="cam470978-note-0002"><p>Abbreviations: NLR, neutrophil&#x02010;to&#x02010;lymphocyte ratio; TLS, tertiary lymphoid structure.</p></fn></table-wrap-foot></table-wrap><p>Log&#x02010;rank testing revealed that TLS status, patient age at diagnosis, CD8+ T cell density, and nerve invasion were significant predictors of overall survival (OS) in MIBC patients (Table&#x000a0;<xref rid="cam470978-tbl-0002" ref-type="table">2</xref>, Table&#x000a0;<xref rid="cam470978-supitem-0004" ref-type="supplementary-material">S3</xref>). Longer OS was exhibited in the TLS&#x02010;positive group compared to the TLS&#x02010;negative group (Figure&#x000a0;<xref rid="cam470978-fig-0001" ref-type="fig">1D</xref>). Although patients with high TLS density (TLS&#x02010;high) demonstrated a trend toward longer OS than those with low TLS density (TLS&#x02010;low), this trend was not statistically significant (Figure&#x000a0;<xref rid="cam470978-fig-0001" ref-type="fig">1E</xref>). In addition to the evaluation of TLS status and other clinicopathological factors in relation to OS, a comprehensive evaluation was performed. Cox regression analysis identified TLS status (hazard ratio [HR] 1.701, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05) and patient age at diagnosis (HR 0.556, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05) as independent prognostic factors for OS (Table&#x000a0;<xref rid="cam470978-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="cam470978-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Univariate and multivariate analysis of overall survival in MIBC.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Variables</th><th align="center" valign="bottom" rowspan="1" colspan="1">Univariate</th><th align="center" colspan="2" valign="bottom" rowspan="1">Multivariate</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">TLS (negative vs. positive)</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.701 (1.018&#x02013;2.842)</td><td align="center" valign="top" rowspan="1" colspan="1">0.043</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (&#x0003c;&#x02009;70&#x02009;year vs. &#x02265;&#x02009;70&#x02009;year)</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.556 (0.341&#x02013;0.9070</td><td align="center" valign="top" rowspan="1" colspan="1">0.019</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD8+ cell density (low vs. high)</td><td align="center" valign="top" rowspan="1" colspan="1">0.029</td><td align="center" valign="top" rowspan="1" colspan="1">1.214 (0.744&#x02013;1.982)</td><td align="center" valign="top" rowspan="1" colspan="1">0.438</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nerve invasion (without vs. with)</td><td align="center" valign="top" rowspan="1" colspan="1">0.009</td><td align="center" valign="top" rowspan="1" colspan="1">0.641 (0.379&#x02013;1.087)</td><td align="center" valign="top" rowspan="1" colspan="1">0.099</td></tr></tbody></table><table-wrap-foot id="cam470978-ntgp-0003"><fn id="cam470978-note-0003"><p>Abbreviations: MIBC, muscle&#x02010;invasive bladder cancer; TLS, tertiary lymphoid structure.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="cam470978-fig-0001"><label>FIGURE 1</label><caption><p>TLS in MIBC. TLS was mainly formed by the aggregation of B cells and T cells (B, C), and most of them are located at the edge of the tumor (A). The OS of patients in the TLS&#x02010;positive group was significantly longer than that in the TLS&#x02010;negative group (D), and the OS of patients in TLS&#x02010;high group was longer than that in TLS&#x02010;low group, but not significantly (E).</p></caption><graphic xlink:href="CAM4-14-e70978-g001" position="anchor" id="jats-graphic-3"/></fig></sec><sec id="cam470978-sec-0014"><label>3.2</label><title>
<styled-content style="fixed-case" toggle="no">TLS</styled-content> Primarily Exerts Anti&#x02010;Tumor Effects via B Cells</title><p>To ascertain the primary effector cells involved in TLS, several crucial tumor&#x02010;infiltrating lymphocytes (TILs) within the samples, including CD8+ T cells, B cells, and plasma cells, were evaluated. A significant correlation was observed between TLS and the density of these TILs (Figure&#x000a0;<xref rid="cam470978-fig-0002" ref-type="fig">2A&#x02013;C</xref>). The TILs were subsequently stratified into high&#x02010; and low&#x02010;density groups to assess the prognostic relevance of TLS within each stratum. Notably, in the subgroup with high&#x02010;density B cells, TLS were found to be significantly associated with improved OS. In contrast, no substantial correlation was identified between TLS and OS in the high&#x02010;density CD8+ T cell and plasma cell subgroups (Figure&#x000a0;<xref rid="cam470978-fig-0002" ref-type="fig">2D&#x02013;I</xref>), indicating a predominant role for B cells in mediating the anti&#x02010;tumor effects of TLS.</p><fig position="float" fig-type="FIGURE" id="cam470978-fig-0002"><label>FIGURE 2</label><caption><p>The relationship between TLS and tumor&#x02010;infiltrating lymphocytes in MIBC. The densities of CD8+ T cells (A), B cells (B) and plasma cells (C) in the TLS&#x02010;positive group were significantly higher than that in the TLS&#x02010;negative group. In the cases with high densities of B cells (D), low densities of CD8+ T cells (G) or low densities of plasma cells (I), TLS&#x02010;positive patients had longer OS than TLS&#x02010;negative patients. However, there was no significant differences in OS between TLS&#x02010;positive and TLS&#x02010;negative groups in the cases with low&#x02010;density B cells (E), high&#x02010;density CD8+ T cells (F) or high&#x02010;density plasma cells (H). *, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05; **, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01; ***, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001.</p></caption><graphic xlink:href="CAM4-14-e70978-g003" position="anchor" id="jats-graphic-5"/></fig></sec><sec id="cam470978-sec-0015"><label>3.3</label><title>Correlation Between <styled-content style="fixed-case" toggle="no">TLS</styled-content> and Molecular Characteristics</title><p>Within our cohort, 1006 variants across 282 genes were identified (Figure&#x000a0;<xref rid="cam470978-fig-0003" ref-type="fig">3A</xref>). High TMB (TMB&#x02009;&#x02265;&#x02009;10) was observed in 56% (45/80) of cases, with only one case exhibiting MSI, which was positive for TLS. The most frequently mutated genes were <italic toggle="yes">TP53</italic> (68%) and <italic toggle="yes">TERT</italic> (66%), followed by <italic toggle="yes">ARID1A</italic>, <italic toggle="yes">PIK3CA</italic>, and <italic toggle="yes">EP300</italic>. Comparative analysis of the mutation rates among the top 50 genes revealed a lower incidence of <italic toggle="yes">TP53</italic> mutations in TLS&#x02010;positive cases compared to TLS&#x02010;negative ones (53.8% vs. 80.5%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.011). Additionally, higher mutation rates for <italic toggle="yes">CDKN1A</italic> (15.4% vs. 0%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.011) and <italic toggle="yes">FAT1</italic> (20.5% vs. 4.9%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.045) were observed in TLS&#x02010;positive cases. Examination of canonical cancer&#x02010;related pathways disclosed no significant TLS&#x02010;status dependent differences, except for the cell cycle pathway (Table&#x000a0;<xref rid="cam470978-supitem-0005" ref-type="supplementary-material">S4</xref>).</p><fig position="float" fig-type="FIGURE" id="cam470978-fig-0003"><label>FIGURE 3</label><caption><p>The molecular characteristics of TLS in MIBC. (A) Mutational spectrum of the patients grouped according to TLS status. (B) Heatmap for comparison of genomic alteration frequencies between TLS&#x02010;positive and TLS&#x02010;negative groups. *, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></caption><graphic xlink:href="CAM4-14-e70978-g005" position="anchor" id="jats-graphic-7"/></fig></sec><sec id="cam470978-sec-0016"><label>3.4</label><title>
<styled-content style="fixed-case" toggle="no">
<italic toggle="no">TP53</italic>
</styled-content> Mutations Inhibited <styled-content style="fixed-case" toggle="no">TLS</styled-content> Production by Inhibiting the Immunogenicity of Neoantigens</title><p>Given the prevalence of <italic toggle="yes">TP53</italic> mutations, we delved deeper into their association with TLS to elucidate why such mutations are associated with a reduction in TLS frequency. <italic toggle="yes">TP53</italic> mutations in our cohort were predominantly located in exons 4&#x02013;8, which are critical DNA&#x02010;binding domains (Figure&#x000a0;<xref rid="cam470978-fig-0004" ref-type="fig">4A</xref>). This distribution is in line with existing literature [<xref rid="cam470978-bib-0010" ref-type="bibr">10</xref>]. Patients with <italic toggle="yes">TP53</italic> mutations in these exons, excluding exon 6 due to a small sample size, showed a tendency toward fewer TLS. When focusing on disruptive <italic toggle="yes">TP53</italic> mutations&#x02014;defined as those involving truncating mutations or nonsynonymous alterations in the L2 to L3 loop region [<xref rid="cam470978-bib-0011" ref-type="bibr">11</xref>] &#x02014;the trends, while present, were less pronounced.</p><fig position="float" fig-type="FIGURE" id="cam470978-fig-0004"><label>FIGURE 4</label><caption><p>Association between TLS and <italic toggle="yes">TP53</italic> mutations and TMB. (A) The rates of TLS&#x02010;positive in cases with <italic toggle="yes">TP53</italic> wild type (WT) status, <italic toggle="yes">TP53</italic> exons4&#x02010;8 mutations, <italic toggle="yes">TP53</italic> non&#x02010;exons4&#x02010;8 mutations, <italic toggle="yes">TP53</italic> disruptive mutations and <italic toggle="yes">TP53</italic> non&#x02010;disruptive mutations. Association between TLS status and TMB in all 80 cases (B), <italic toggle="yes">TP53</italic> WT cases (C) and <italic toggle="yes">TP53</italic> mutation type (MT) cases (D). **, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01; ns, <italic toggle="yes">p</italic>&#x02009;&#x0003e;&#x02009;0.05.</p></caption><graphic xlink:href="CAM4-14-e70978-g004" position="anchor" id="jats-graphic-9"/></fig><p>Neoantigens, generated by somatic mutations, are hypothesized to activate immune responses by being presented to effector cells, with their abundance closely tied to TMB [<xref rid="cam470978-bib-0012" ref-type="bibr">12</xref>]. We postulated that a high TMB might trigger TLS formation. However, no significant correlation was observed between TMB and TLS, CD8+ T cells, or B cells within our cohort (Figure&#x000a0;<xref rid="cam470978-fig-0004" ref-type="fig">4B</xref>, Figure&#x000a0;<xref rid="cam470978-supitem-0001" ref-type="supplementary-material">S1</xref>). Intriguingly, when <italic toggle="yes">TP53</italic> mutation status was taken into account, TMB showed a significant correlation with TLS in <italic toggle="yes">TP53</italic> wild&#x02010;type patients, but not in those with <italic toggle="yes">TP53</italic> mutations (Figure&#x000a0;<xref rid="cam470978-fig-0004" ref-type="fig">4C,D</xref>, Figure&#x000a0;<xref rid="cam470978-supitem-0001" ref-type="supplementary-material">S1</xref>). Collectively, these findings suggest that <italic toggle="yes">TP53</italic> mutations may suppress the immunogenic potential of neoantigens, thereby inhibiting TLS formation.</p></sec></sec><sec sec-type="discussion" id="cam470978-sec-0017"><label>4</label><title>Discussion</title><p>TLSs are acknowledged for their antitumor effects in a wide range of malignancies, including colorectal, breast, and non&#x02010;small cell lung cancers [<xref rid="cam470978-bib-0013" ref-type="bibr">13</xref>, <xref rid="cam470978-bib-0014" ref-type="bibr">14</xref>, <xref rid="cam470978-bib-0015" ref-type="bibr">15</xref>, <xref rid="cam470978-bib-0016" ref-type="bibr">16</xref>]. However, in clear cell renal carcinoma, an inverse relationship is observed, where increased TLS density is linked to poorer patient outcomes [<xref rid="cam470978-bib-0007" ref-type="bibr">7</xref>]. Our study adds to this body of evidence by demonstrating that TLSs in MIBC are associated with a lower T&#x02010;stage and serve as an independent predictor of favorable prognosis.</p><p>The precise mechanisms through which TLS contribute to anti&#x02010;tumor processes remain elusive but are likely to involve cellular immunity. Numerous studies have established a link between TLS and the presence of Th1 and CD8+ T cells [<xref rid="cam470978-bib-0008" ref-type="bibr">8</xref>, <xref rid="cam470978-bib-0017" ref-type="bibr">17</xref>]. In our cohort, although TLS were significantly associated with CD8+ T cell density, the beneficial prognostic impact of TLS was not attributed to CD8+ T cells but rather to B cells. This is consistent with existing literature [<xref rid="cam470978-bib-0018" ref-type="bibr">18</xref>, <xref rid="cam470978-bib-0019" ref-type="bibr">19</xref>, <xref rid="cam470978-bib-0020" ref-type="bibr">20</xref>], which suggests that TLS predominantly exert their antitumor effects through B cells. B cells have the potential to impact tumors either by differentiating into plasma cells that produce tumor&#x02010;specific antibodies or by acting as antigen&#x02010;presenting cells to enhance T cell responses [<xref rid="cam470978-bib-0021" ref-type="bibr">21</xref>]. Plasma cells could be generated in mature TLS but are absent or rare in immature TLS [<xref rid="cam470978-bib-0019" ref-type="bibr">19</xref>, <xref rid="cam470978-bib-0020" ref-type="bibr">20</xref>]. In our cohort, there were few mature TLS, mostly immature TLS. However, TLS were still significantly associated with plasma cells, suggesting that immature TLS have some mechanism by which plasma cells could be recruited. Similar to CD8+ T cells, the prognostic effect of TLS did not depend on a high density of plasma cells, suggesting that B cells in TLS may primarily play an antigen&#x02010;presenting role.</p><p>The genesis of TLS is a multifaceted process influenced by various lympho&#x02010;organogenic chemokines in response to inflammatory stimuli [<xref rid="cam470978-bib-0022" ref-type="bibr">22</xref>, <xref rid="cam470978-bib-0023" ref-type="bibr">23</xref>]. The interplay between TLS and genetic mutations within tumor cells is not fully understood. The association between TLS and mutations in the PI3K&#x02010;mTOR pathway in renal clear cell carcinoma [<xref rid="cam470978-bib-0007" ref-type="bibr">7</xref>], <italic toggle="yes">BRAF</italic> mutations in colorectal carcinoma [<xref rid="cam470978-bib-0018" ref-type="bibr">18</xref>], and <italic toggle="yes">APC</italic> germline mutations in hepatoblastoma [<xref rid="cam470978-bib-0024" ref-type="bibr">24</xref>] has been reported in studies. Our NGS analysis of 80 MIBC cases revealed that TLS&#x02010;positive tumors had lower <italic toggle="yes">TP53</italic> mutation rates and higher <italic toggle="yes">CDKN1A</italic> and <italic toggle="yes">FAT1</italic> mutation rates, suggesting that certain genetic alterations may either promote or inhibit TLS formation.</p><p>
<italic toggle="yes">TP53</italic> mutations, a common occurrence in human cancers [<xref rid="cam470978-bib-0011" ref-type="bibr">11</xref>, <xref rid="cam470978-bib-0025" ref-type="bibr">25</xref>], can influence the immune microenvironment in complex ways [<xref rid="cam470978-bib-0026" ref-type="bibr">26</xref>, <xref rid="cam470978-bib-0027" ref-type="bibr">27</xref>]. While <italic toggle="yes">TP53</italic> mutations are known to elevate TMB [<xref rid="cam470978-bib-0028" ref-type="bibr">28</xref>, <xref rid="cam470978-bib-0029" ref-type="bibr">29</xref>] and may therefore be expected to enhance TLS formation and immune response, our results indicate that <italic toggle="yes">TP53</italic> mutations may actually suppress TLS formation. This suppression could be due to an inhibitory effect on the immunogenicity of neoantigens derived from TMB. Our findings underscore the need for a deeper understanding of the intricate relationship between <italic toggle="yes">TP53</italic> mutations, TLS, and the immune microenvironment in MIBC.</p></sec><sec sec-type="conclusions" id="cam470978-sec-0018"><label>5</label><title>Conclusions</title><p>Our analysis of TLS in MIBC has identified them as a favorable prognostic factor, whose formation appears to be modulated by <italic toggle="yes">TP53</italic> mutations. Despite these insights, limitations warrant further investigation. Elucidating the specific mechanisms underlying TLS formation will be instrumental in enhancing our comprehensive understanding of the immune microenvironment in MIBC.</p></sec><sec id="cam470978-sec-0025"><title>Author Contributions</title><p>
<bold>Xiaodong Teng:</bold> conceptualization (equal), funding acquisition (equal), project administration (equal), supervision (equal), writing &#x02013; original draft (equal). <bold>Zhen Chen:</bold> data curation (lead), methodology (equal), validation (equal). <bold>Yanfeng Bai:</bold> data curation (equal), formal analysis (equal), validation (equal). <bold>Hui Cao:</bold> data curation (equal), methodology (equal). <bold>Jing Zhang:</bold> funding acquisition (equal), methodology (equal). <bold>Liming Xu:</bold> methodology (equal). <bold>Kaihua Liu:</bold> methodology (equal), software (equal). <bold>Yuqian Shi:</bold> methodology (equal). <bold>Yang Shao:</bold> methodology (equal).</p></sec><sec id="cam470978-sec-0019"><title>Ethics Statement</title><p>The present study and an application to waive informed consent were approved by the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine.</p></sec><sec sec-type="conclusions" id="cam470978-sec-0020"><title>Consent</title><p>The authors have nothing to report.</p></sec><sec sec-type="COI-statement" id="cam470978-sec-0021"><title>Conflicts of Interest</title><p>Kaihua Liu, Yuqian Shi, Yang Shao are employees of Nanjing Geneseeq Technology Inc. other authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cam470978-supitem-0001" position="float" content-type="local-data"><caption><p>
<bold>Figure S1.</bold> Association between TMB and tumor&#x02010;infiltrating lymphocytes under different TP53 mutation statuses in MIBC. TMB and the densities of CD8+ T cells (A), B cells (B), plasma cells (C) in all cases; TMB and the densities of CD8&#x02009;+&#x02009;T cells (D), B cells (E), plasma cells (F) in TP53 WT cases; TMB and the densities of CD8&#x02009;+&#x02009;T cells (G), B cells (H), plasma cells (I) in TP53 MT cases; WT, wild type; MT, mutation type.</p></caption><media xlink:href="CAM4-14-e70978-s001.pdf"/></supplementary-material><supplementary-material id="cam470978-supitem-0002" position="float" content-type="local-data"><caption><p>
<bold>Table&#x000a0;S1.</bold> The information of antibodies used in this study.</p></caption><media xlink:href="CAM4-14-e70978-s004.docx"/></supplementary-material><supplementary-material id="cam470978-supitem-0003" position="float" content-type="local-data"><caption><p>
<bold>Table&#x000a0;S2.</bold> The 425 cancer&#x02010;related genes included in the GeneseeqPrime panel.</p></caption><media xlink:href="CAM4-14-e70978-s003.xlsx"/></supplementary-material><supplementary-material id="cam470978-supitem-0004" position="float" content-type="local-data"><caption><p>
<bold>Table&#x000a0;S3.</bold> The correlation between clinicopathological characteristic (or combined factors) and OS in patients with MIBC.</p></caption><media xlink:href="CAM4-14-e70978-s002.docx"/></supplementary-material><supplementary-material id="cam470978-supitem-0005" position="float" content-type="local-data"><caption><p>
<bold>Table&#x000a0;S4.</bold> The percentage of samples with alterations in each of the signaling pathways in which genomic alterations related to MIBC development in terms of TLS status.</p></caption><media xlink:href="CAM4-14-e70978-s005.docx"/></supplementary-material></sec></body><back><ack id="cam470978-sec-0022"><title>Acknowledgements</title><p>We would like to thank Qi Zhang for the help in statistical analysis.</p></ack><sec sec-type="data-availability" id="cam470978-sec-0024"><title>Data Availability Statement</title><p>The datasets used and during the current study are available from the corresponding author on reasonable request.</p></sec><ref-list content-type="cited-references" id="cam470978-bibl-0001"><title>References</title><ref id="cam470978-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cam470978-cit-0001">
<string-name>
<given-names>A. T.</given-names>
<surname>Lenis</surname>
</string-name>, <string-name>
<given-names>P. M.</given-names>
<surname>Lec</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Chamie</surname>
</string-name>, and <string-name>
<given-names>M. D.</given-names>
<surname>Mshs</surname>
</string-name>, &#x0201c;<article-title>Bladder Cancer: A Review</article-title>,&#x0201d; <source>JAMA</source>
<volume>324</volume>, no. <issue>19</issue> (<year>2020</year>): <fpage>1980</fpage>&#x02013;<lpage>1991</lpage>.<pub-id pub-id-type="pmid">33201207</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cam470978-cit-0002">
<string-name>
<given-names>T. N.</given-names>
<surname>Schumacher</surname>
</string-name> and <string-name>
<given-names>D. S.</given-names>
<surname>Thommen</surname>
</string-name>, &#x0201c;<article-title>Tertiary Lymphoid Structures in Cancer</article-title>,&#x0201d; <source>Science</source>
<volume>375</volume> (<year>2022</year>): <elocation-id>eabf9419</elocation-id>.<pub-id pub-id-type="pmid">34990248</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cam470978-cit-0003">
<string-name>
<given-names>J. L.</given-names>
<surname>Teillaud</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Houel</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Panouillot</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Riffard</surname>
</string-name>, and <string-name>
<given-names>M. C.</given-names>
<surname>Dieu&#x02010;Nosjean</surname>
</string-name>, &#x0201c;<article-title>Tertiary Lymphoid Structures in Anticancer Immunity</article-title>,&#x0201d; <source>Nature Reviews. Cancer</source>
<volume>24</volume> (<year>2024</year>): <fpage>629</fpage>&#x02013;<lpage>646</lpage>.<pub-id pub-id-type="pmid">39117919</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cam470978-cit-0004">
<string-name>
<given-names>X.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Yao</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Xie</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Tertiary Lymphoid Structures as Potential Biomarkers for Cancer Prediction and Prognosis</article-title>,&#x0201d; <source>International Immunopharmacology</source>
<volume>140</volume> (<year>2024</year>): <elocation-id>112790</elocation-id>.<pub-id pub-id-type="pmid">39088920</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cam470978-cit-0005">
<string-name>
<given-names>M.</given-names>
<surname>Koti</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Bivalacqua</surname>
</string-name>, <string-name>
<given-names>P. C.</given-names>
<surname>Black</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Adaptive Immunity in Genitourinary Cancers</article-title>,&#x0201d; <source>European Urology Oncology</source>
<volume>6</volume> (<year>2023</year>): <fpage>263</fpage>&#x02013;<lpage>272</lpage>.<pub-id pub-id-type="pmid">37069029</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cam470978-cit-0006">
<string-name>
<given-names>M.</given-names>
<surname>Koti</surname>
</string-name>, <string-name>
<given-names>A. S.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>K. Y. M.</given-names>
<surname>Ren</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Tertiary Lymphoid Structures Associate With Tumour Stage in Urothelial Bladder Cancer</article-title>,&#x0201d; <source>Bladder Cancer</source>
<volume>3</volume> (<year>2017</year>): <fpage>259</fpage>&#x02013;<lpage>267</lpage>.<pub-id pub-id-type="pmid">29152550</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cam470978-cit-0007">
<string-name>
<given-names>T.</given-names>
<surname>Masuda</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Tanaka</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Takamatsu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Unique Characteristics of Tertiary Lymphoid Structures in Kidney Clear Cell Carcinoma: Prognostic Outcome and Comparison With Bladder Cancer</article-title>,&#x0201d; <source>Journal for Immunotherapy of Cancer</source>
<volume>10</volume> (<year>2022</year>): <elocation-id>e003883</elocation-id>.<pub-id pub-id-type="pmid">35314433</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cam470978-cit-0008">
<string-name>
<given-names>L.</given-names>
<surname>Vanhersecke</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Brunet</surname>
</string-name>, <string-name>
<given-names>J. P.</given-names>
<surname>Guegan</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Mature Tertiary Lymphoid Structures Predict Immune Checkpoint Inhibitor Efficacy in Solid Tumors Independently of Pd&#x02010;l1 Expression</article-title>,&#x0201d; <source>Nature Cancer</source>
<volume>2</volume> (<year>2021</year>): <fpage>794</fpage>&#x02013;<lpage>802</lpage>.<pub-id pub-id-type="pmid">35118423</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cam470978-cit-0009">
<string-name>
<given-names>K.</given-names>
<surname>Shitara</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Ozguroglu</surname>
</string-name>, <string-name>
<given-names>Y. J.</given-names>
<surname>Bang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Pembrolizumab Versus Paclitaxel for Previously Treated, Advanced Gastric or Gastro&#x02010;Oesophageal Junction Cancer (Keynote&#x02010;061): A Randomised, Open&#x02010;Label, Controlled, Phase 3 Trial</article-title>,&#x0201d; <source>Lancet</source>
<volume>392</volume> (<year>2018</year>): <fpage>123</fpage>&#x02013;<lpage>133</lpage>.<pub-id pub-id-type="pmid">29880231</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cam470978-cit-0010">
<string-name>
<given-names>L. A.</given-names>
<surname>Donehower</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Soussi</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Korkut</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Integrated Analysis of tp53 Gene and Pathway Alterations in the Cancer Genome Atlas</article-title>,&#x0201d; <source>Cell Reports</source>
<volume>28</volume> (<year>2019</year>): <fpage>3010</fpage>.<pub-id pub-id-type="pmid">31509758</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cam470978-cit-0011">
<string-name>
<given-names>J.</given-names>
<surname>Blagih</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Zani</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Chakravarty</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Cancer&#x02010;Specific Loss of p53 Leads to a Modulation of Myeloid and t Cell Responses</article-title>,&#x0201d; <source>Cell Reports</source>
<volume>30</volume> (<year>2020</year>): <fpage>481</fpage>&#x02013;<lpage>496</lpage>.<pub-id pub-id-type="pmid">31940491</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cam470978-cit-0012">
<string-name>
<given-names>T. N.</given-names>
<surname>Schumacher</surname>
</string-name> and <string-name>
<given-names>R. D.</given-names>
<surname>Schreiber</surname>
</string-name>, &#x0201c;<article-title>Neoantigens in Cancer Immunotherapy</article-title>,&#x0201d; <source>Science</source>
<volume>348</volume> (<year>2015</year>): <fpage>69</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">25838375</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cam470978-cit-0013">
<string-name>
<given-names>G.</given-names>
<surname>Trajkovski</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Ognjenovic</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Karadzov</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Tertiary Lymphoid Structures in Colorectal Cancers and Their Prognostic Value</article-title>,&#x0201d; <source>Open Access Macedonian Journal of Medical Sciences</source>
<volume>6</volume> (<year>2018</year>): <fpage>1824</fpage>&#x02013;<lpage>1828</lpage>.<pub-id pub-id-type="pmid">30455756</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cam470978-cit-0014">
<string-name>
<given-names>N. N.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>F. J.</given-names>
<surname>Qu</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Liu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Prognostic Impact of Tertiary Lymphoid Structures in Breast Cancer Prognosis: A Systematic Review and Meta&#x02010;Analysis</article-title>,&#x0201d; <source>Cancer Cell International</source>
<volume>21</volume> (<year>2021</year>): <fpage>536</fpage>.<pub-id pub-id-type="pmid">34654433</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cam470978-cit-0015">
<string-name>
<given-names>M.</given-names>
<surname>Brunet</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Crombe</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Cousin</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Mature Tertiary Lymphoid Structure Is a Specific Biomarker of Cancer Immunotherapy and Does Not Predict Outcome to Chemotherapy in Non&#x02010;Small&#x02010;Cell Lung Cancer</article-title>,&#x0201d; <source>Annals of Oncology</source>
<volume>33</volume> (<year>2022</year>): <fpage>1084</fpage>&#x02013;<lpage>1085</lpage>.<pub-id pub-id-type="pmid">35764273</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cam470978-cit-0016">
<string-name>
<given-names>Z.</given-names>
<surname>Zhao</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Ding</surname>
</string-name>, <string-name>
<given-names>Z. B.</given-names>
<surname>Lin</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Relationship Between Tertiary Lymphoid Structure and the Prognosis and Clinicopathologic Characteristics in Solid Tumors</article-title>,&#x0201d; <source>International Journal of Medical Sciences</source>
<volume>18</volume> (<year>2021</year>): <fpage>2327</fpage>&#x02013;<lpage>2338</lpage>.<pub-id pub-id-type="pmid">33967609</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cam470978-cit-0017">
<string-name>
<given-names>Q.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>He</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Cd8(+) t Cells Located in Tertiary Lymphoid Structures Are Associated With Improved Prognosis in Patients With Gastric Cancer</article-title>,&#x0201d; <source>Oncology Letters</source>
<volume>20</volume> (<year>2020</year>): <fpage>2655</fpage>&#x02013;<lpage>2664</lpage>.<pub-id pub-id-type="pmid">32782582</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cam470978-cit-0018">
<string-name>
<given-names>F.</given-names>
<surname>Posch</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Silina</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Leibl</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Maturation of Tertiary Lymphoid Structures and Recurrence of Stage Ii and Iii Colorectal Cancer</article-title>,&#x0201d; <source>Oncoimmunology</source>
<volume>7</volume> (<year>2018</year>): <elocation-id>e1378844</elocation-id>.<pub-id pub-id-type="pmid">29416939</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cam470978-cit-0019">
<string-name>
<given-names>C.</given-names>
<surname>Germain</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Gnjatic</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Tamzalit</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Presence of b Cells in Tertiary Lymphoid Structures Is Associated With a Protective Immunity in Patients With Lung Cancer</article-title>,&#x0201d; <source>American Journal of Respiratory and Critical Care Medicine</source>
<volume>189</volume> (<year>2014</year>): <fpage>832</fpage>&#x02013;<lpage>844</lpage>.<pub-id pub-id-type="pmid">24484236</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cam470978-cit-0020">
<string-name>
<given-names>D. R.</given-names>
<surname>Kroeger</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Milne</surname>
</string-name>, and <string-name>
<given-names>B. H.</given-names>
<surname>Nelson</surname>
</string-name>, &#x0201c;<article-title>Tumor&#x02010;Infiltrating Plasma Cells Are Associated With Tertiary Lymphoid Structures, Cytolytic t&#x02010;Cell Responses, and Superior Prognosis in Ovarian Cancer</article-title>,&#x0201d; <source>Clinical Cancer Research</source>
<volume>22</volume> (<year>2016</year>): <fpage>3005</fpage>&#x02013;<lpage>3015</lpage>.<pub-id pub-id-type="pmid">26763251</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cam470978-cit-0021">
<string-name>
<given-names>H.</given-names>
<surname>Zhao</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Zhou</surname>
</string-name>, and <string-name>
<given-names>X.</given-names>
<surname>Ren</surname>
</string-name>, &#x0201c;<article-title>Insights Into Tertiary Lymphoid Structures in the Solid Tumor Microenvironment: Anti&#x02010;Tumor Mechanism, Functional Regulation, and Immunotherapeutic Strategies</article-title>,&#x0201d; <source>Cancer Biology &#x00026; Medicine</source>
<volume>18</volume> (<year>2021</year>): <fpage>981</fpage>&#x02013;<lpage>991</lpage>.<pub-id pub-id-type="pmid">34553849</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cam470978-cit-0022">
<string-name>
<given-names>S. A.</given-names>
<surname>van de Pavert</surname>
</string-name> and <string-name>
<given-names>R. E.</given-names>
<surname>Mebius</surname>
</string-name>, &#x0201c;<article-title>New Insights Into the Development of Lymphoid Tissues</article-title>,&#x0201d; <source>Nature Reviews. Immunology</source>
<volume>10</volume> (<year>2010</year>): <fpage>664</fpage>&#x02013;<lpage>674</lpage>.</mixed-citation></ref><ref id="cam470978-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cam470978-cit-0023">
<string-name>
<given-names>G. W.</given-names>
<surname>Jones</surname>
</string-name>, <string-name>
<given-names>D. G.</given-names>
<surname>Hill</surname>
</string-name>, and <string-name>
<given-names>S. A.</given-names>
<surname>Jones</surname>
</string-name>, &#x0201c;<article-title>Understanding Immune Cells in Tertiary Lymphoid Organ Development: It Is all Starting to Come Together</article-title>,&#x0201d; <source>Frontiers in Immunology</source>
<volume>7</volume> (<year>2016</year>): <fpage>401</fpage>.<pub-id pub-id-type="pmid">27752256</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cam470978-cit-0024">
<string-name>
<given-names>G.</given-names>
<surname>Morcrette</surname>
</string-name>, <string-name>
<given-names>T. Z.</given-names>
<surname>Hirsch</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Badour</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Apc Germline Hepatoblastomas Demonstrate Cisplatin&#x02010;Induced Intratumor Tertiary Lymphoid Structures</article-title>,&#x0201d; <source>Oncoimmunology</source>
<volume>8</volume> (<year>2019</year>): <elocation-id>e1583547</elocation-id>.<pub-id pub-id-type="pmid">31069152</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cam470978-cit-0025">
<string-name>
<given-names>P. A.</given-names>
<surname>Muller</surname>
</string-name> and <string-name>
<given-names>K. H.</given-names>
<surname>Vousden</surname>
</string-name>, &#x0201c;<article-title>Mutant p53 in Cancer: New Functions and Therapeutic Opportunities</article-title>,&#x0201d; <source>Cancer Cell</source>
<volume>25</volume>, no. <issue>3</issue> (<year>2014</year>): <fpage>304</fpage>&#x02013;<lpage>317</lpage>.<pub-id pub-id-type="pmid">24651012</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cam470978-cit-0026">
<string-name>
<given-names>E. R.</given-names>
<surname>Kastenhuber</surname>
</string-name> and <string-name>
<given-names>S. W.</given-names>
<surname>Lowe</surname>
</string-name>, &#x0201c;<article-title>Putting p53 in Context</article-title>,&#x0201d; <source>Cell</source>
<volume>170</volume> (<year>2017</year>): <fpage>1062</fpage>&#x02013;<lpage>1078</lpage>.<pub-id pub-id-type="pmid">28886379</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cam470978-cit-0027">
<string-name>
<given-names>S. S.</given-names>
<surname>Mello</surname>
</string-name> and <string-name>
<given-names>L. D.</given-names>
<surname>Attardi</surname>
</string-name>, &#x0201c;<article-title>Deciphering p53 Signaling in Tumor Suppression</article-title>,&#x0201d; <source>Current Opinion in Cell Biology</source>
<volume>51</volume> (<year>2018</year>): <fpage>65</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">29195118</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cam470978-cit-0028">
<string-name>
<given-names>C.</given-names>
<surname>Willis</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Fiander</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Tran</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Tumor Mutational Burden in Lung Cancer: A Systematic Literature Review</article-title>,&#x0201d; <source>Oncotarget</source>
<volume>10</volume> (<year>2019</year>): <fpage>6604</fpage>&#x02013;<lpage>6622</lpage>.<pub-id pub-id-type="pmid">31762941</pub-id>
</mixed-citation></ref><ref id="cam470978-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cam470978-cit-0029">
<string-name>
<given-names>L.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Li</surname>
</string-name>, and <string-name>
<given-names>X.</given-names>
<surname>Wang</surname>
</string-name>, &#x0201c;<article-title>Cancer Type&#x02010;Dependent Correlations Between tp53 Mutations and Antitumor Immunity</article-title>,&#x0201d; <source>DNA Repair (Amst)</source>
<volume>88</volume> (<year>2020</year>): <elocation-id>102785</elocation-id>.<pub-id pub-id-type="pmid">32007736</pub-id>
</mixed-citation></ref></ref-list></back></article>